Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-07-31

Clinical Trial Update: A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of ustekinumab (CNTO 1275) in Crohn's disease has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Centocor, Inc. | Conditions: Crohn Disease | Phase 2 | Status: COMPLETED | Results posted: 2013-07-31